Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹41,252 Cr
Revenue (TTM)
₹3,801 Cr
Net Profit (TTM)
₹1,021 Cr
ROE
49.4 %
ROCE
67.6 %
P/E Ratio
40.4
P/B Ratio
20.6
Industry P/E
28.7
EV/EBITDA
28.1
Div. Yield
2.2 %
Debt to Equity
0
Book Value
₹118.3
EPS
₹59.4
Face value
10
Shares outstanding
169,406,034
CFO
₹5,490.85 Cr
EBITDA
₹6,911.46 Cr
Net Profit
₹4,395.50 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
| -1.5 | -6.4 | -5.6 | -9.5 | 23.7 | 11.5 | 3.8 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
| 10.8 | 15.4 | 43.9 | -24.9 | 9.0 | -0.5 | 7.5 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
|
2,437.6 | 41,252.1 | 3,800.7 | 1,021.0 | 32.2 | 55 | 40.4 | 20.6 |
| 26,375.0 | 55,882.2 | 6,824.1 | 1,524.1 | 25.9 | 37 | 36.7 | 12.7 | |
| 5,351.5 | 63,950.5 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27 | 4.6 | |
| 1,269.0 | 73,703.7 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 21.1 | 2.1 | |
| 382.6 | 61,967.3 | 16,827.4 | 629.6 | 9.6 | -0.1 | 102.6 | 1.6 | |
| 1,543.6 | 39,123.7 | 9,504.5 | 947.8 | 15.9 | 14.6 | 43 | 5.0 | |
| 2,302.4 | 1,05,236.5 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.7 | 5.1 | |
| 2,103.1 | 86,793.0 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 48.8 | 5.5 | |
| 1,778.3 | 4,26,781.7 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 39.1 | 5.3 | |
| 899.6 | 90,435.3 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.3 | 3.4 |
1 min read•By Research Desk
2 min read•By Mohammed Ekramul Haque
3 min read•By Research Desk
4 min read•By Research Desk
2 min read•By Research Desk
Nasdaq Tremors Rock Dalal Street
2 min read•By Markets Desk
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis,... hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India. Read more
Incorporated
1924
Chairman
Renu Sud Karnad
Managing Director
Bhushan Akshikar
Group
Glaxosmithkline - MNC
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Glaxosmithkline Pharmaceuticals Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Glaxosmithkline Pharmaceuticals Ltd is ₹2,437.60 (NSE) and ₹2,435.10 (BSE) as of 18-Mar-2026 IST. Glaxosmithkline Pharmaceuticals Ltd has given a return of 23.71% in the last 3 years.
The P/E ratio of Glaxosmithkline Pharmaceuticals Ltd is 40.40 times as on 18-Mar-2026, a 41 premium to its peers’ median range of 28.70 times.
The P/B ratio of Glaxosmithkline Pharmaceuticals Ltd is 20.59 times as on 18-Mar-2026, a 351 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
52.55
|
24.79
|
|
2024
|
55.80
|
18.42
|
|
2023
|
36.73
|
12.87
|
|
2022
|
16.62
|
10.58
|
|
2021
|
68.13
|
16.51
|
The 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd are Rs 3,515.70 and Rs 2,220.30 as of 19-Mar-2026.
Glaxosmithkline Pharmaceuticals Ltd has a market capitalisation of ₹ 41,252 Cr as on 18-Mar-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Glaxosmithkline Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹8.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.